自然美(00157.HK)發布法證審閱之主要發現 續停牌
自然美(00157.HK)公布,為回應核數師有關集團向某些分銷商所作銷售以及某些個人分銷商及客戶向集團結算其付款的方式的查詢,審核委員會已委聘普華永道為法證會計團隊就集團若干中國全資附屬公司的問題進行法證審閱。
審核委員會及董事會已審閱法證審閱的主要發現,認為儘管有「主要限制」一節所載限制,但法證會計團隊已進行徹底法證審閱,且法證審閱已在可行情況下全面調查核數師提出的問題。
公司認為法證審閱識別的問題並無對集團業務營運、財務狀況及或有負債造成任何重大不利影響。儘管自今年3月25日以來暫停買賣,但集團繼續其正常業務營運。
該公司繼續停牌至另行發布通告為止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.